HIGH POINT, N.C., Aug. 12, 2025 (GLOBE NEWSWIRE) -- vTv Therapeutics Inc. (Nasdaq: VTVT), a late-stage biopharmaceutical company focused on the development of cadisegliatin, a potential first-in-class oral adjunctive therapy to insulin being investigated for the treatment of type 1 diabetes (T1D), today reported financial results for the second quarter ended June 30, 2025, and provided an update on recent corporate developments.
“The randomization of the first participant in our CATT1 Phase 3 trial earlier this month reflects our continued momentum in advancing cadisegliatin,” said Paul Sekhri, Chairman, President and CEO of vTv Therapeutics. “Cadisegliatin is designed to selectively activate glucokinase in the liver, a differentiated approach that may improve glycemic control and reduce the risk of hypoglycemia when used alongside insulin. Hypoglycemic episodes remain frequent, life-disruptive, and sometimes life-threatening for people with type 1 diabetes. We believe cadisegliatin could play a meaningful role in addressing this large unmet medical need.”
Recent Company Highlights
Second Quarter 2025 Financial Results
| vTv Therapeutics Inc. Condensed Consolidated Balance Sheets (in thousands) | ||||||||
| June 30, 2025 | December 31, 2024 | |||||||
| (Unaudited) | ||||||||
| Assets | ||||||||
| Current assets: | ||||||||
| Cash and cash equivalents | $ | 25,922 | $ | 36,746 | ||||
| Prepaid expenses | 359 | 1,192 | ||||||
| Other current assets | 93 | 175 | ||||||
| Total current assets | 26,374 | 38,113 | ||||||
| Property and equipment, net | 16 | 28 | ||||||
| Operating lease right-of-use assets | 58 | 125 | ||||||
| Total assets | $ | 26,448 | $ | 38,266 | ||||
| Liabilities and Stockholders’ Equity | ||||||||
| Current liabilities: | ||||||||
| Accounts payable and accrued expenses | $ | 5,216 | $ | 5,027 | ||||
| Current portion of operating lease liabilities | 79 | 169 | ||||||
| Total current liabilities | 5,295 | 5,196 | ||||||
| Contract liabilities, net of current portion | 18,669 | 18,669 | ||||||
| Warrant liability, related party | 31 | 57 | ||||||
| Warrant liability | 48 | 43 | ||||||
| Total liabilities | 24,043 | 23,965 | ||||||
| Commitments and contingencies | ||||||||
| Stockholders’ equity: | ||||||||
| Class A Common Stock | 26 | 26 | ||||||
| Class B Common Stock | 6 | 6 | ||||||
| Additional paid-in capital | 313,586 | 311,885 | ||||||
| Accumulated deficit | (310,856 | ) | (299,718 | ) | ||||
| Total stockholders’ equity attributable to vTv Therapeutics Inc. | 2,762 | 12,199 | ||||||
| Noncontrolling interest | (357 | ) | 2,102 | |||||
| Total stockholders’ equity | 2,405 | 14,301 | ||||||
| Total liabilities and stockholders’ equity | $ | 26,448 | $ | 38,266 | ||||
| vTv Therapeutics Inc. Condensed Consolidated Statements of Operations (in thousands, except per share data) | ||||||||||||||||
| Three Months Ended June 30, | Six Months Ended June 30, | |||||||||||||||
| 2025 | 2024 | 2025 | 2024 | |||||||||||||
| (Unaudited) | (Unaudited) | |||||||||||||||
| Revenue | $ | — | $ | — | $ | — | $ | 1,000 | ||||||||
| Operating expenses: | ||||||||||||||||
| Research and development | 4,103 | 3,439 | 6,933 | 6,088 | ||||||||||||
| General and administrative | 3,618 | 3,716 | 7,291 | 7,694 | ||||||||||||
| Total operating expenses | 7,721 | 7,155 | 14,224 | 13,782 | ||||||||||||
| Operating loss | (7,721 | ) | (7,155 | ) | (14,224 | ) | (12,782 | ) | ||||||||
| Interest income | 275 | 553 | 606 | 632 | ||||||||||||
| Other income (expense), net | 66 | 193 | 21 | (178 | ) | |||||||||||
| Loss before income taxes and noncontrolling interest | (7,380 | ) | (6,409 | ) | (13,597 | ) | (12,328 | ) | ||||||||
| Income tax provision | — | — | — | 100 | ||||||||||||
| Net loss before noncontrolling interest | (7,380 | ) | (6,409 | ) | (13,597 | ) | (12,428 | ) | ||||||||
| Less: net loss attributable to noncontrolling interest | (1,334 | ) | (1,229 | ) | (2,459 | ) | (2,383 | ) | ||||||||
| Net loss attributable to vTv Therapeutics Inc. | $ | (6,046 | ) | $ | (5,180 | ) | $ | (11,138 | ) | $ | (10,045 | ) | ||||
| Net loss attributable to vTv Therapeutics Inc. common shareholders | $ | (6,046 | ) | $ | (5,180 | ) | $ | (11,138 | ) | $ | (10,045 | ) | ||||
| Net loss per share of vTv Therapeutics Inc. Class A common stock, basic and diluted | $ | (0.92 | ) | $ | (0.81 | ) | $ | (1.69 | ) | $ | (1.97 | ) | ||||
| Weighted average number of vTv Therapeutics Inc. Class A common stock, basic and diluted | 6,587,070 | 6,403,444 | 6,584,969 | 5,098,877 | ||||||||||||
About Cadisegliatin
Cadisegliatin (TTP399) is a novel, oral small molecule, liver-selective glucokinase activator being investigated as a potential first-in-class oral adjunctive treatment for type 1 diabetes (T1D). In non-clinical studies, cadisegliatin, acting selectively on the liver, increased the activity of glucokinase independently from insulin which supports clinical investigation of improvement in glycemic control through hepatic glucose uptake and glycogen storage.
Cadisegliatin is under investigation and the safety and efficacy have not been established. There is no guarantee that this product will receive health authority approval or become commercially available for the use being investigated.
About vTv Therapeutics
vTv Therapeutics is a late-stage biopharmaceutical company focused on developing oral, small molecule drug candidates intended to help treat people living with diabetes and other chronic diseases. vTv’s clinical pipeline is led by cadisegliatin, currently in a Phase 3 trial, a potential first-in-class oral glucokinase activator being investigated for the treatment of type 1 diabetes. vTv and its development partners are investigating multiple molecules across different indications for chronic diseases. Learn more at vtvtherapeutics.com or follow the company on LinkedIn or X.
Forward-Looking Statement
This release contains forward-looking statements, which involve risks and uncertainties. These forward-looking statements can be identified by the use of forward-looking terminology, including the terms “anticipate,” “believe,” “could,” “estimate,” “expect,” “intend,” “may,” “plan,” “potential,” “predict,” “project,” “should,” “target,” “will,” “would” and, in each case, their negative or other various or comparable terminology. All statements other than statements of historical facts contained in this release, including statements regarding the timing of our clinical trials, our strategy, future operations, future financial position, future revenue, projected costs, prospects, plans, objectives of management and expected market growth are forward-looking statements. These statements involve known and unknown risks, uncertainties and other important factors that may cause our actual results, performance, or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. Important factors that could cause our results to vary from expectations include those described under the heading “Risk Factors” in our Annual Report on Form 10-K and our other filings with the SEC. These forward-looking statements reflect our views with respect to future events as of the date of this release and are based on assumptions and subject to risks and uncertainties. Given these uncertainties, you should not place undue reliance on these forward-looking statements. These forward-looking statements represent our estimates and assumptions only as of the date of this release and, except as required by law, we undertake no obligation to update or review publicly any forward-looking statements, whether as a result of new information, future events or otherwise after the date of this release. We anticipate that subsequent events and developments will cause our views to change. Our forward-looking statements do not reflect the potential impact of any future acquisitions, merger, dispositions, joint ventures, or investments we may undertake. We qualify all our forward-looking statements by these cautionary statements.
Investor Contact
John Fraunces
LifeSci Advisors, LLC
917-355-2395
This email address is being protected from spambots. You need JavaScript enabled to view it.
Media Contact
Caren Begun
TellMed Strategies
201-396-8551
This email address is being protected from spambots. You need JavaScript enabled to view it.
| Last Trade: | US$14.03 |
| Daily Change: | -0.46 -3.17 |
| Daily Volume: | 1,571 |
| Market Cap: | US$36.760M |
August 07, 2025 May 15, 2025 March 20, 2025 | |
Cue Biopharma is developing the first-ever class of therapeutics for the treatment of cancer that mimic the natural signals, or “Cues”, of the immune system. This novel class of injectable biologics selectively engages and modulates tumor-specific T cells directly within the patient’s body to transform...
CLICK TO LEARN MORE
Astria Therapeutics is a biopharmaceutical company, and our mission is to bring life-changing therapies to patients and families affected by rare and niche allergic and immunological diseases. Our lead program, STAR-0215, is a monoclonal antibody inhibitor of plasma kallikrein in clinical development...
CLICK TO LEARN MORE
